Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly on Thursday said it expects to release King88bet Login data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, a few months earlier than anticipated. The company expects to provide results from a 68-week studi in people with obesity and osteoarthritis of the knee in 2025, according to fourth-quarter earnings slides on its situs. Eli Lilly previously said that phase three studi was expected to finis in February 2026. It is among at least nine closely watched clinical trials on retatrutide, which works differently from the obesity and diabetes treatments on the pasar and appears to be even more efekive at weight loss. "We believe this potential new medicine can King88bet Slot deliver even more weight loss than tirzepatide and it could potentially provide additional health benefits," Daniel Skovronsky, Lilly's chief scientific and medical officer, said during an earnings call on Thu...